Title
Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis

Permalink
https://escholarship.org/uc/item/5s60v4nt

Authors
Itoh, N
Kim, R
Peng, M
et al.

Publication Date
2017-03-15

DOI
10.1016/j.jneuroim.2016.09.017

Peer reviewed
Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis

Noriko Itoh, M.S, Roy Kim, Mavis Peng, Emma DiFilippo, Hadley Johnsonbaugh, Allan MacKenzie-Graham, Ph.D., Rhonda R. Voskuhl, M.D. *

Department of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA

ARTICLE INFO

Article history:
Received 17 May 2016
Accepted 28 September 2016
Available online xxxx

Keywords:
Multiple sclerosis
Experimental autoimmune encephalomyelitis
Estrogen
Pregnancy
Neuroprotection

ABSTRACT

Protective effects of pregnancy during MS have led to clinical trials of estriol, the pregnancy estrogen, in MS. Since estriol binds to estrogen receptor (ER) beta, ER beta ligand could represent a “next generation estriol” treatment. Here, ER beta ligand treatment was protective in EAE in both sexes and across genetic backgrounds. Neuroprotection was shown in spinal cord, sparing myelin and axons, and in brain, sparing neurons and synapses. Longitudinal in vivo MRIs showed decreased brain atrophy in cerebral cortex gray matter and cerebellum during EAE. Investigation of ER beta ligand as a neuroprotective treatment for MS is warranted. © 2016 Elsevier B.V. All rights reserved.

1. Introduction

Multiple sclerosis (MS) is a putative autoimmune disease targeting the central nervous system (CNS) leading to neurodegeneration. Currently approved treatments for MS were designed to modulate peripheral immune responses to decrease CNS inflammation. These treatments reduce relapse rates by about half compared to placebo treatment in clinical trials, with only modest effects on slowing permanent disability accumulation. Many MS treatments are relatively safe and well tolerated. More aggressive anti-inflammatory treatments reduce relapse rates further, but are associated with toxicities related in part to immunosuppression. Rather than escalating to more aggressive anti-inflammatory treatments for better long term disability outcomes, an alternative would be to combine relatively safe anti-inflammatory treatments with a neuroprotective treatment in patients with relapsing remitting MS (Voskuhl, 2016). Such neuroprotective treatments may also benefit progressive MS patients.

“Bedside to Bench to Bedside” research is a way to capitalize on a known clinical observation, mechanistically dissect it at the laboratory bench, then translate basic findings back to the clinic in the form of a novel clinical trial (Voskuhl and Gold, 2012). This approach has a clinical observation as its foundation. In contrast, “Bench to Bedside” research is based on a molecule or pathway thought to be involved in a disease mechanism, with trials designed to block this molecule. The latter approach carries risk that the molecule or pathway of interest may not ultimately be physiologically significant in humans with disease, since most biological processes involve redundant mechanisms and compensatory pathways. Blocking one molecule or pathway may not have a significant effect in complex diseases in humans. This is one reason why pharmaceutical company success rates are low compared to the number of lead candidates initially passing in vitro screening and in vivo preclinical models. The “Bedside to Bench to Bedside” approach mitigates this risk since it starts with a clinical observation known to be physiologically relevant. Mechanisms underlying clinical observations may involve several molecules and complementary pathways. A multifaceted approach may indeed be what is required to impact complex diseases. The “Bedside to Bench to Bedside” approach in drug development is a conceptual shift, since the “Bench to Bedside” approach has focused on the molecule first, with questions of physiologic relevance coming later.

A major clinical observation in MS is that pregnancy is protective (Confavreux et al., 1998). Relapses are decreased by over 70% in the last trimester. Hormones and other factors change during pregnancy, each warranting consideration for mediating this protection. Estriol is an estrogen of pregnancy, distinct from estradiol of ovulatory cycles. It is made by the fetal placental unit and rises progressively during pregnancy to reach high levels in the last trimester (Lindberg et al., 1974). Estriol was given to mice with experimental autoimmune encephalomyelitis (EAE) with promising results (Voskuhl et al., 1997). Since estriol binds to estrogen receptor (ER) beta, ER beta ligand could represent a “next generation estriol” treatment. Here, ER beta ligand treatment was protective in EAE in both sexes and across genetic backgrounds. Neuroprotection was shown in spinal cord, sparing myelin and axons, and in brain, sparing neurons and synapses. Longitudinal in vivo MRIs showed decreased brain atrophy in cerebral cortex gray matter and cerebellum during EAE.

Please cite this article as: Itoh, N., et al., Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis., J. Neuroimmunol. (2016), http://dx.doi.org/10.1016/j.jneuroim.2016.09.017

http://dx.doi.org/10.1016/j.jneuroim.2016.09.017
0165-5728/© 2016 Elsevier B.V. All rights reserved.
encephalomyelitis (EAE) at doses to induce a level in the blood physiologic with mouse pregnancy, and disease protection was observed (Kim et al., 1999). This disease protection was found in both female and male mice, in both relapsing and progressive EAE models, and when administered either before or after EAE onset, reviewed in (Spence and Voskuhl, 2012). Estriol is a relatively weak estrogen, acting on estrogen receptor (ER) alpha and ER beta, with higher affinity for ER beta (Katzenellenbogen, 1984; Kuiper et al., 1997). ER alpha ligand treatment during EAE was protective early in EAE (Morales et al., 2006), was shown to be anti-inflammatory during peripheral immune responses (Lelu et al., 2011; Morales et al., 2006), and neuroprotective by binding to astrocytes to reduce CCL2 and immune infiltration in the CNS (Kim et al., 2014; Spence et al., 2011). ER beta ligand treatment was protective later during EAE (Tiwari-Woodruff et al., 2007), did not alter peripheral immune responses (Tiwari-Woodruff et al., 2007), and did not target astrocytes (Spence et al., 2013). Instead ER beta ligand and estriol each had protective effects on microglia and dendritic cells (Drew and Chavis, 2000; Du et al., 2011; Papenfuss et al., 2011; Saijo et al., 2011). Also, ER beta ligand was shown to act on oligodendrocytes to increase remyelination (Crawford et al., 2010; Khalaj et al., 2013). In EAE (Ziehn et al., 2012; Ziehn et al., 2010) and non-EAE (Kramar et al., 2009; Liu et al., 2008) ovarioctomized mice, estriol and estrogen receptor beta ligand treatment improves cognitive behavioral testing and hippocampal synaptic plasticity, respectively. Coming full circle, these latter preclinical data are consistent with another clinical observation in humans, namely cognitive dysfunction occurs in healthy women after surgical ovarioectomy (Sherwin, 1988).

Two trials have been completed, and one is ongoing (www.clinicaltrials.gov), with oral estriol treatment of 8 mg per day in women with MS to induce an estriol level in blood that recapitulates pregnancy. The first pilot clinical trial used the biomarker of enhancing lesions on monthly MRIs as the primary outcome measure. There was an over 70% reduction in enhancing lesions with estril treatment compared to pretreatment in a single arm crossover design ( Sicotte et al., 2002). The second trial was a Phase 2b, placebo-controlled, multicenter trial with relapse rate reduction as the primary outcome measure (Voskuhl et al., 2016). Relapses were reduced by a third to a half more in the estril plus glatiramer acetate group compared to the glatiramer acetate plus placebo. Exploratory analyses showed that higher estril blood levels correlated with reduced relapses and with reduced enhancing lesion positive scans. Higher estril blood levels also correlated with improved cognitive testing performance. Trends for protective effects on cerebral cortical gray matter atrophy by MRI were also observed, particularly in patients who were enhancing lesion negative, suggesting neuroprotective effects (Voskuhl et al., 2016).

Oral estriol is taken at doses of 1–2 mg per day in Europe and Asia to alleviate menopausal symptoms. Estriol has been considered the safest of the estrogens for decades, likely due to its preferential binding to ER beta over ER alpha, not toxicities related to breast and uterus are mediated by ER alpha, not ER beta (Head, 1998; Lauritzen, 1987; Takahashi et al., 2000). While safety was shown in women with MS to induce an estriol level in blood that recapitulates pregnancy, the generic ER beta ligand, diarylpropionitrile (DPN, Tocris Biosciences), was dissolved in Miglyol 812 N liquid oil (Sasol North America) and sesame oil (Sigma Aldrich) at 15 mg/ml for delivery of a 30 mg/kg treatment dose which was administered subcutaneously every other day, achieving a final dose of 15 mg/kg/day. The generic ER beta ligand, diarylpropionitrile (DPN, Tocris Biosciences), was dissolved in 10% molecular-grade ethanol and diluted with 90% Miglyol 812 N liquid oil (Sasol North America) to achieve a final dose of 8 mg/kg per day, as described (Tiwari-Woodruff et al., 2007).

2. Materials and methods

2.1. Animals

C57BL/6 and NOD mice, 8 weeks of age, were purchased from Jackson Laboratories (Bar Harbor, ME). Animals were maintained under environmentally controlled conditions in a 12-hour light/dark cycle with access to food and water ad libitum. All procedures were done in accordance with the guidelines of the National Institutes of Health and the Chancellor's Animal Research Committee of the University of California, Los Angeles Office for the Protection of Research Subjects.

2.2. Reagents/treatments

ER beta ligand (AC186) was provided by Acadia Pharmaceuticals (McFarland et al., 2013). It was dissolved in Miglyol 812 N liquid oil (Sasol North America) or sesame oil (Sigma Aldrich) at 15 mg/ml for delivery of a 30 mg/kg treatment dose which was administered subcutaneously every other day, achieving a final dose of 15 mg/kg/day. The generic ER beta ligand, diarylpropionitrile (DPN, Tocris Biosciences), was dissolved in 10% molecular-grade ethanol and diluted with 90% Miglyol 812 N liquid oil (Sasol North America) to achieve a final dose of 8 mg/kg per day, as described (Tiwari-Woodruff et al., 2007).

2.3. EAE

C57BL/6 and NOD mice were injected subcutaneously with Myelin Oligodendrocyte Glycoprotein (MOG), amino acids 35–55 (200 μg/animal, American Peptides), emulsified in complete Freund’s adjuvant (CFA) and supplemented with Mycobacterium tuberculosis H37rα (300 μg/animal, Difco Laboratories), over two sites drained by left inguinal and auxiliary lymph nodes in a total volume of 0.1 ml/mouse. One week later, a booster immunization was delivered over contra lateral lymph nodes. Pertussis toxin (500 ng/mouse) (List Biological Laboratories, Inc.) was injected intraperitoneally on days 0 and 2. Animals were monitored daily for EAE signs based on a standard EAE 0–5 scale scoring system: 0—healthy, 1—complete loss of tail tone, 2—loss of righting reflex, 3—partial paralysis, 4—complete paralysis of one or both hind limbs, and 5—moribund. Treatments with ER beta ligand or vehicle were initiated at the first clear signs of clinical disease (EAE grade 2 at day 13–15) and continued to the endpoint of the experiment, as described (Wisdom et al., 2013).

2.4. Rotarod testing

Motor behavior was tested up to two times per week for each mouse using a rotarod apparatus (Med Associates Inc., St. Albans, VT). Briefly, animals were placed on a rotating horizontal cylinder for a maximum of 200 s. The amount of time the mouse remained walking on the cylinder, without falling, was recorded. Each mouse was tested on a speed of 3–30 rpm and given three trials for any given day. The three trials were averaged to report a single value for an individual mouse, and then averages were calculated for all animals within a given treatment group, as described (Du et al., 2014).

2.5. Histological preparation

Mice were exposed to a lethal dose of isoflurane and perfused transcardially with ice-cold 1× PBS for 8–15 min, followed by 10% formalin for 10–15 min. Spinal cords and brains were dissected and submerged in 10% formalin overnight at 4 °C, followed by 30% sucrose in PBS for 24 h. Tissues were embedded in 75% gelatin/15% sucrose solution for cryostat sectioning then post-fixed overnight in 10% formalin and cryoprotected in 30% sucrose. The embedded tissues were stored in −80 °C after flash frozen in dry ice. 40 μm thick free-floating spinal...
cord cross-sections, and sagittal brain sections were obtained with a microscope b cryostat (model HM505E) at −20 °C. Tissues were collected serially and stored in 1× PBS with 1% sodium azide in 4 °C until immunohistochemistry (Spence et al., 2013).

2.6. Immunofluorescence

Prior to histological staining, 40-μm thick free-floating sections were thoroughly washed with 1× PBS to remove residual sodium azide. In the case of anti-MBP labeling, tissue sections were processed with an additional 1 h incubation with 5% glacial acetic acid in 100-proof ethanol at room temperature (RT). After washing tissue sections were permeabilized with 0.3% TritonX-100 and 2% normal goat serum in 1× PBS for 30 min at RT and blocked with 10% normal goat serum in 1× PBS for 1 h. Tissues were then incubated with primary antibodies overnight in 4 °C. The following primary antibody (Ab) were used: Rat anti-MBP (Millipore) at 1:1000 dilutions, Rabbit anti-NF200 (Sigma Aldrich) at 1:750 dilutions, Rabbit anti-beta-APP (Life Technologies) at 1:200 dilutions, Mouse anti-NeuN at 1:1000 dilutions (Millipore), Rabbit anti-PSD95, and Rat anti-CD45 at 1:1500 dilutions (Millipore). The next day tissues were washed and incubated with secondary antibodies conjugated to Cy5 or Cy3 (Millipore) for 1 h at RT. A nuclear stain DAPI (2 ng/ml; Molecular Probes) was added 10 min prior to final washes after secondary Ab incubation. Sections were mounted on slides, allowed to semi-dry, and cover slipped in fluoromount G (Fisher Scientific). IgG-control experiments were performed for all primary Ab, and only non-immunoreactive tissues under these conditions were analyzed (Spence et al., 2013).

2.7. Chromagen immunohistochemistry

Tissue sections were thoroughly washed with 1× PBS to remove residual sodium azide and treated with 3% hydrogen peroxide for 30 min at RT and then simultaneously blocked with 10% NGS and permeabilized with 0.3% TritonX-100 in 1× PBS for 1 h at room temperature. Tissues were then incubated with primary antibodies overnight in 4 °C. The following primary antibodies were used: Rat anti-CD3 at 1:2000 dilutions (BD Pharmingen), anti-Calbindin D28K at 1:1000 dilutions (Millipore), Rabbit anti-Iba1 at 1:10,000 dilutions (Wako Chemicals), and Rabbit anti-β-APP (Life Technologies) at 1:750 dilutions (Millipore). Tissue sections then followed with secondary Ab labeling at 1:1000 dilutions (Vector labs) for 1 h at room temperature and then with Avidin-Biotin Conjugation solution (Vector Labs) for 1 h at RT. Tissue sections were treated with DAB peroxidase substrate (Vector labs) according to manufacturer instructions. IgG-control experiments were performed for all primary Ab, and only non-immunoreactive tissues under these conditions were analyzed (MacKenzie-Graham et al., 2009).

2.8. Microscopy and quantification

Spinal cord cross-sections from each mouse were captured under microscope at 10× magnification. To quantify demyelination in the spinal cord and cerebellum, white matter was manually delineated on the basis of DAPI staining, and MBP staining intensity was calculated and reported in the sampled area. Axonal damage was assessed by counting beta-APP+ cells in a confocal 10× microscope in spinal cord. Axonal densities were calculated by counting the number of NF200+ or NeuN+ neuronal cells in a 10× confocal image in the sampled area of the captured tissue section. Cerebellar Purkinje (Calbindin+) cells were manually counted using a brightfield 10× microscope over the entire sagittal cerebellum. CD3+, and Iba1+ cells were manually quantified under a confocal 10× microscope for CD45+ cells or a brightfield 10× microscope for CD3+ and Iba1+ cells (Spence et al., 2013).

2.9. MRI acquisition

Mice were anesthetized with isoflurane, respiratory rate was monitored, and temperature was maintained at 37 °C. In vivo magnetic resonance imaging was performed on a 200 mm horizontal bore 7.0 T Bruker imaging spectrometer with a micro-imaging gradient insert with a maximum gradient strength of 100 G/cm and 30 mm birdcage RF coil (Bruker Instruments, Billerica, MA). Imaging parameters were as follows: rapid-acquisition with relaxation enhancement (RARE) sequence, matrix dimensions = 256 × 128 × 64; field of view = 3.84 cm × 1.92 cm × 0.96 cm; repetition time (TR) = 3500 ms; apparent time to echo (apparent TE) = 32 ms; echo train length = 16; total scan time = 37 mins. Spatial resolution was 150 μm³ per voxel (MacKenzie-Graham et al., 2012a).

2.10. MRI analysis

In vivo magnetic resonance images were analyzed as previously described (Spence et al., 2014). Briefly, images were skull-stripped using the Brain Surface Extractor (BSE) in BrainSuite 11a (Shattuck and Leahy, 2001) and bias-field inhomogeneities removed using the N3 correction (Sled et al., 1998). A minimum deformation atlas (MDA) was produced and images were spatially and intensity normalized to it using a rigid-body transformation. Cerebral cortices and cerebella were manually labeled on the atlas as described (Spence et al., 2014) and the labels were then warped onto the individual spatially-normalized images to produce standardized estimates of gray matter volumes in individual subjects. All automated image processing was performed using the LONI Pipeline Processing Environment (Rex et al., 2003) on an 8-processor core Mac Pro computer (Apple, Cupertino, CA (MacKenzie-Graham et al., 2012a).

2.11. Statistical analysis

The significance of EAE severity and rotator performance were determined by repeated measures ANOVA. Immunohistochemical data was analyzed by one-way ANOVA. Bonferroni tests (GraphPad Prism6) were used to adjust for multiple comparisons. Global and regional brain volume changes in EAE mice and healthy controls were compared with a repeated measures ANOVA in SPSS 22 (IBM, Armonk, NY). If Mauchly's test indicated that the assumption of sphericity had been violated (p < 0.05), then the degrees of freedom were corrected using Huynh-Feldt estimates of sphericity. Regression analysis and Welch's t-tests were performed in Excel 2011 (Microsoft, Redmond, WA). All results are presented as mean ± standard error.

3. Theory

To address the need for development of a neuroprotective treatment for MS, this work will focus on a “next generation estriol treatment”, namely ER beta ligand treatment. Potential neuroprotective effects will be investigated in EAE, not only in spinal cord, but also in cerebral cortex and cerebellum, using in vivo longitudinal MRI and neuropathology.

4. Results

4.1. ER beta ligand treatment reduces chronic EAE in females and males across genetic backgrounds

Active EAE was induced using MOG 35–55 peptide in female C57BL/6 mice. Treatment with ER beta ligand or vehicle control was initiated after EAE induction, at the first signs of clinical disease and continued every other day to the end of experiment. Clinical EAE severity scores were reduced in mice treated with ER beta ligand as compared to vehicle control (Table 1, Fig. 1A, left). Furthermore, when mice were...
assessed for the number of seconds they could remain on the rotarod, the ER beta ligand treated group performed better than the vehicle control group (Fig. 1A, right). These data showing clinical disease protection were not limited to one sex or one genetic background, but can also be beneficial in female mice or could also be beneficial in males, we then induced active EAE in male C57BL/6 mice, and again observed significant protection in both standard EAE and rotarod clinical outcomes (Table 1, Fig. 1B). Next, to ascertain whether beneficial effects of ER beta ligand treatment in chronic EAE were limited to one genetic background or could also be protective across genetic backgrounds, active EAE was induced in female NOD mice with chronic EAE. ER beta ligand treatment was also protective in NOD females with chronic EAE (Table 1). Together these results demonstrate that beneficial effects of ER beta ligand treatment are not limited to one sex or one genetic background, but can be observed in both sexes across various genetic backgrounds.

### 4.2. Effect of ER beta ligand treatment on spinal cord neuropathology

Classic immunohistochemistry of spinal cord white matter showed axonal loss (by reduced NF200 staining) p < 0.005, axonal damage (by increased beta-APP staining) p < 0.05, and demyelination (by decreased MBP staining) p < 0.005, in vehicle treated EAE compared to healthy controls. ER beta ligand treatment of EAE mice after disease onset preserved axons and myelin (ER beta ligand EAE vs vehicle treated EAE: axons p < 0.05; axonal damage p < 0.05; myelin p < 0.005), (Fig. 1C). Assessment of spinal cord white matter inflammation in vehicle treated EAE compared to healthy controls showed increased inflammation (by CD45 staining) p < 0.0001, increased macrophages/activated microglia (by Iba-1 staining with glialoid morphology) p < 0.005, and increased T lymphocytes (by CD3 staining) p < 0.05. ER beta ligand treatment of EAE partially reduced inflammation as detected by CD45 staining, p < 0.05, with this driven by the reduction in macrophages/activated microglia, p < 0.05, not T lymphocytes.

### 4.3. ER beta ligand treatment reduces brain atrophy on MRI during chronic EAE

Chronic EAE in C57BL/6 mice entails not only demyelination and axonal loss in spinal cord, but also neuronal and synaptic loss in cerebellum and cerebral cortex (Brown and Sawchenko, 2007; MacKenzie-Graham et al., 2012a; Mangiardi et al., 2011; Ziehen et al., 2010), and previous MRI studies have shown atrophy of brain, cerebral cortex, and cerebellum during chronic EAE (Aharoni et al., 2013; Lepore et al., 2013; MacKenzie-Graham et al., 2012a; MacKenzie-Graham et al., 2009; Spence et al., 2014). Here, we determined whether treatment with ER beta ligand during EAE could spare brain atrophy by MRI. ER beta ligand treated or vehicle treated EAE mice underwent in vivo, longitudinal MRI scanning at day 0, 30 and 60 of EAE. Treatments were initiated after clinical disease onset. Age- and sex-matched healthy controls were scanned in parallel. Whole brain, cerebrum cortex, and cerebellar volumes were determined at each time point (Fig. 2). Brain volume remained stable over time in the healthy control group, but showed a gradual decrease in the vehicle treated EAE group (time x group interaction p = 1.1 × 10⁻⁶). The mean volume of whole brain of mice sixty days after disease induction was 490 mm³ ± 1.7 mm³ (mean ± SEM) in healthy mice and 478 mm³ ± 1.2 mm³ in EAE mice, indicating a 2.4% decrease (p = 5.3 × 10⁻⁶) in volume. To assess the effect of ER beta ligand treatment on whole brain atrophy, we then determined the rate of whole brain atrophy in ER beta ligand-treated mice compared to vehicle-treated EAE mice, and found that the mean brain volume decrease was less in ER beta ligand-treated EAE mice (Fig. 2D).

Cerebral cortex volumes of healthy control and EAE mice showed a similar pattern. Cerebral cortex volumes were stable in the healthy control group, while gradually decreasing in the vehicle treated EAE group (time x group interaction p = 4.0 × 10⁻⁶). The mean volume of the cerebral cortex at sixty days after disease induction was 72.3 mm³ ± 0.41 mm³ in healthy mice and 68.9 mm³ ± 0.6 mm³ in EAE mice, a 4.6% decrease (p = 1.5 × 10⁻⁴) in volume. Cerebral cortex atrophy rates were less in ER beta ligand-treated EAE mice compared to vehicle-treated EAE mice (time x group interaction p = 0.0035). The mean volume of the cerebral cortex at sixty days after disease induction was 70.8 mm³ ± 0.5 mm³ in ER beta ligand-treated EAE, a 2.7% difference (p = 0.014) in volume between ER beta ligand treated and vehicle treated EAE mice (Fig. 2E).

Similarly, a progressive loss of cerebellar volume during EAE was observed in vehicle treated EAE mice compared to healthy mice (time x group interaction p = 1.1 × 10⁻⁵). The volume of the whole cerebellum at sixty days after disease induction was 53.2 mm³ ± 0.3 mm³ in healthy mice and 50.0 mm³ ± 0.4 mm³ in EAE mice, a 6.0% decrease (p = 3.1 × 10⁻⁶) in volume. ER beta ligand treatment decreased the rate of volume loss compared to vehicle treatment (time x group interaction p = 9.5 × 10⁻⁵). The mean volume of the whole cerebellum at sixty days after disease induction was 51.8 mm³ ± 0.4 mm³ in ER beta ligand-treated EAE mice, a 3.6% difference (p = 0.0013) in volume between ER beta ligand treated and vehicle treated EAE mice (Fig. 2F).

These in vivo longitudinal MRI results on cerebellar atrophy in gonadally intact mice with EAE extend previous cross-sectional, ex vivo imaging studies in ovarioctomized EAE mice that demonstrated preservation of cerebellar cortex volumes during treatment with estradiol, ER alpha ligand, or ER beta ligand treatment (MacKenzie-Graham et al., 2012b).
4.4. ER beta ligand treatment reduces neuropathology in cerebral cortex during chronic EAE

Since longitudinal MRIs showed that ER beta ligand treatment significantly reduced gray matter atrophy in the cerebral cortex during EAE (Fig. 2E), we next determined the effect of ER beta ligand treatment on underlying pathology in cerebral cortical gray matter. Immunofluorescence analysis of cerebral cortical gray matter in vehicle-treated EAE compared to healthy controls (black) showed increased inflammation (CD45 staining), increased macrophages/activated microglia (Iba-1 staining with globoid morphology) and T lymphocytes (CD3 staining). ER beta ligand treated EAE mice (red) had reduced pan-immune (CD45) and macrophage/activated microglia (Iba-1 globoid) staining, with no decrease in T lymphocyte (CD3) staining. For neuropathology, three to five mice were examined per treatment group. CD45 counts included dorsal column of spinal cord, while Iba-1 and CD3 counts were done for whole spinal cord white matter including dorsal, lateral and ventral regions. ***p < 0.0001, **p < 0.005, *p < 0.05, with p-values determined by one-way ANOVA. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

4.5. ER beta ligand treatment reduces cerebellar neuropathology during chronic EAE

Since longitudinal MRIs showed that ER beta ligand treatment significantly reduced cerebellar atrophy during EAE (Fig. 2F), we determined the effect of ER beta ligand treatment on neuropathology in white and
gray matter of cerebellum. Cerebellar white matter showed demyelination, \( p < 0.005 \), and axonal loss, \( p < 0.005 \), in vehicle treated EAE compared to healthy controls. ER beta ligand treatment of EAE mice restored myelin and axons (ER beta ligand EAE vs vehicle EAE: myelin \( p < 0.05 \), axons \( p < 0.005 \)) to levels near those in healthy controls (Fig. 4A, B).

Cerebellar gray matter showed decreased Purkinje numbers in the Purkinje cells layer, \( p < 0.05 \), and decreased PSD-95 synaptic staining in the molecular layer, \( p < 0.005 \), in vehicle treated EAE compared to healthy controls (Fig. 4C, D). ER beta ligand treated EAE mice showed increased Purkinje cells and synapses (ER beta ligand EAE vs, vehicle EAE: Purkinje cells, \( p < 0.005 \), synapses, \( p < 0.005 \)) to levels near those in healthy controls (Fig. 4).

5. Discussion

ER beta ligand treatment provides protection from chronic EAE including, and extending beyond, the spinal cord (Fig. 1). Specifically, ER beta ligand treatment initiated after disease onset was shown to slow brain atrophy by MRI in cerebral cortex and cerebellum (Fig. 2), preserve myelin and axons in white matter and restore neuronal and

![Figure 2](image-url) Whole brain, cerebral cortical and cerebellar atrophy in EAE are reduced by ER beta ligand treatment. (A–C) Anatomic delineations of cerebral cortex (green) and cerebellum (yellow) overlaid onto the coronal, sagittal and horizontal planes of a minimum deformation atlas comprising all images from all groups of mice. (D) Mean whole brain volume over time in healthy controls (black), ER beta ligand–treated mice with EAE (red) and vehicle–treated mice with EAE (blue) at d0, d30 and d60. ER beta ligand–treated EAE mice exhibit less brain atrophy than vehicle–treated EAE mice as early as d30. (E) Mean cerebral cortex volume in the same groups. ER beta ligand–treated EAE mice exhibit less atrophy in the cerebral cortex than vehicle–treated EAE mice by d60. (F) Mean cerebellar volumes in the same groups. ER beta ligand–treated EAE mice exhibit less cerebellar atrophy than vehicle–treated EAE mice by d60. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

![Figure 3](image-url) ER beta ligand treatment of EAE: protective effects in cerebral cortical gray matter. Representative 10× images of cerebral cortical gray matter neurons stained for NeuN in green (A) and synapses stained for the postsynaptic protein PSD-95 in red (B) in healthy control (left), vehicle treated EAE (middle), and ER beta ligand treated EAE (right). Quantification of immunofluorescence staining is shown in bar graphs. Vehicle treated EAE mice (blue bars) had fewer NeuN+ cortical neurons and less PSD-95+ synapses in the cerebral cortex as compared to age-matched healthy controls (black bars). ER beta ligand treated EAE mice (red bars), as compared to vehicle treated EAE mice (blue bars), had higher numbers of NeuN+ cortical neurons and PSD-95+ synapses in the cerebral cortex, with values comparable to age-matched healthy controls. In A, cc indicates corpus callosum adjacent to cerebral cortex. In B, tissues were counter stained with the nuclear stain DAPI (blue). Three to five mice were examined for each treatment group. **\( p < 0.005 \), *\( p < 0.05 \), with p-values determined by one-way ANOVA. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
synaptic loss in gray matter (Figs. 3, 4). These preclinical data warrant consideration of ER beta ligand treatment as a novel neuroprotective treatment for MS.

ER beta ligand can be considered a “next generation estriol” treatment, since estriol is a naturally occurring estrogen with higher affinity for ER beta than ER alpha (Katzenellenbogen, 1984; Kuiper et al., 1997). Comparing and contrasting effects of estriol versus ER beta ligand treatment in EAE can disentangle which effects of estriol treatment may be mediated by ER beta. Preclinical studies using estriol treatment in EAE, like those using ER beta ligand treatment, have shown beneficial effects in spinal cord including sparing of myelin and axons and improved standard EAE severity scores (Kim et al., 1999). Beyond spinal cord in EAE, estriol treatment spared hippocampal CA1 atrophy, reduced neuronal and synaptic loss, and improved cognitive function as assessed by electrophysiology (Ziehn et al., 2012). Here, ER beta ligand treatment in EAE spared cerebral cortical atrophy by MRI (Fig. 2) and reduced neuronal and synaptic loss (Fig. 3). A major difference between estriol and ER beta ligand treatment in EAE is that estriol was anti-inflammatory during peripheral autoantigen specific responses (Bebo et al., 2001; Kim et al., 1999; Papenfuss et al., 2011), while ER beta ligand treatment was not (Du et al., 2011; Tiwari-Woodruff et al., 2007). Since a role for ER alpha in estrogen mediated anti-inflammatory effects in the immune system have been shown using take away (ER alpha knock out mice) (Liu et al., 2003; Polanczyk et al., 2003) and add back (treatments with ER alpha specific ligands) experiments (Morales et al., 2006), this is likely due to low level ER alpha ligation in the immune system with estriol, but not with ER beta ligand, treatment.

Results in MS clinical trials using estriol treatment, combined with known differences in properties of estriol versus ER beta ligand, can be used to hypothesize what might occur in an MS trial using ER beta ligand treatment. Estriol treatment in MS trials had anti-inflammatory effects in peripheral blood mononuclear cells (Gold et al., 2009; Soldan et al., 2003), but this may not occur with ER beta ligand treatment due to the lack of ER alpha ligand binding. Estriol treatment reduced gadolinium enhancing lesions in an MS trial with enhancing lesions on monthly MRIs as the primary outcome (Scicotte et al., 2002), but this too may not occur in a trial using ER beta ligand treatment since enhancing lesions are linked to peripheral immune activation. Estriol treatment reduced relapse rates in an MS trial with relapses as the primary outcome (Voskuhl, 2016). This also may not occur in a trial using ER beta ligand treatment given that enhancing lesions are a biomarker for relapses. However, exploratory outcomes in the estriol Phase 2b trial, designed to detect a decrease in relapse rates, showed that higher estriol levels correlated with improved cognitive function as compared to placebo treatment (Voskuhl, 2016). This was unlikely due to anti-inflammatory effects of estriol since FDA approved disease modifying treatments in MS have not shown significant cognitive improvement over and above placebo treatment during trials. Instead this suggests a direct neuroprotective effect of estriol treatment on cognition (Voskuhl, 2016), as was previously observed in EAE (Ziehn et al., 2012). Given the neuroprotective effects of ER beta ligand treatment in cerebral cortex in EAE (Fig. 3), it is likely that ER beta ligand treatment would also improve cognitive function in an MS trial. Another interesting exploratory finding in the estriol Phase 2b trial was that there was less cerebral cortical gray matter sparing cerebral cortical atrophy by MRI (Fig. 2) and reduced neuronal and synaptic loss (Fig. 3). A major difference between estriol and ER beta ligand treatment in EAE is that estriol was anti-inflammatory during peripheral autoantigen specific responses (Bebo et al., 2001; Kim et al., 1999; Papenfuss et al., 2011), while ER beta ligand treatment was not (Du et al., 2011; Tiwari-Woodruff et al., 2007). Since a role for ER alpha in estrogen mediated anti-inflammatory effects in the immune system have been shown using take away (ER alpha knock out mice) (Liu et al., 2003; Polanczyk et al., 2003) and add back (treatments with ER alpha specific ligands) experiments (Morales et al., 2006), this is likely due to low level ER alpha ligation in the immune system with estriol, but not with ER beta ligand, treatment.

Results in MS clinical trials using estriol treatment, combined with known differences in properties of estriol versus ER beta ligand, can be used to hypothesize what might occur in an MS trial using ER beta ligand treatment. Estriol treatment in MS trials had anti-inflammatory effects in peripheral blood mononuclear cells (Gold et al., 2009; Soldan et al., 2003), but this may not occur with ER beta ligand treatment due to the lack of ER alpha ligand binding. Estriol treatment reduced gadolinium enhancing lesions in an MS trial with enhancing lesions on monthly MRIs as the primary outcome (Scicotte et al., 2002), but this too may not occur in a trial using ER beta ligand treatment since enhancing lesions are linked to peripheral immune activation. Estriol treatment reduced relapse rates in an MS trial with relapses as the primary outcome (Voskuhl, 2016). This also may not occur in a trial using ER beta ligand treatment given that enhancing lesions are a biomarker for relapses. However, exploratory outcomes in the estriol Phase 2b trial, designed to detect a decrease in relapse rates, showed that higher estriol levels correlated with improved cognitive function as compared to placebo treatment (Voskuhl, 2016). This was unlikely due to anti-inflammatory effects of estriol since FDA approved disease modifying treatments in MS have not shown significant cognitive improvement over and above placebo treatment during trials. Instead this suggests a direct neuroprotective effect of estriol treatment on cognition (Voskuhl, 2016), as was previously observed in EAE (Ziehn et al., 2012). Given the neuroprotective effects of ER beta ligand treatment in cerebral cortex in EAE (Fig. 3), it is likely that ER beta ligand treatment would also improve cognitive function in an MS trial. Another interesting exploratory finding in the estriol Phase 2b trial was that there was less cerebral cortical gray matter sparing cerebral cortical atrophy by MRI (Fig. 2) and reduced neuronal and synaptic loss (Fig. 3). A major difference between estriol and ER beta ligand treatment in EAE is that estriol was anti-inflammatory during peripheral autoantigen specific responses (Bebo et al., 2001; Kim et al., 1999; Papenfuss et al., 2011), while ER beta ligand treatment was not (Du et al., 2011; Tiwari-Woodruff et al., 2007). Since a role for ER alpha in estrogen mediated anti-inflammatory effects in the immune system have been shown using take away (ER alpha knock out mice) (Liu et al., 2003; Polanczyk et al., 2003) and add back (treatments with ER alpha specific ligands) experiments (Morales et al., 2006), this is likely due to low level ER alpha ligation in the immune system with estriol, but not with ER beta ligand, treatment.

Results in MS clinical trials using estriol treatment, combined with known differences in properties of estriol versus ER beta ligand, can be used to hypothesize what might occur in an MS trial using ER beta ligand treatment. Estriol treatment in MS trials had anti-inflammatory effects in peripheral blood mononuclear cells (Gold et al., 2009; Soldan et al., 2003), but this may not occur with ER beta ligand treatment due to the lack of ER alpha ligand binding. Estriol treatment reduced gadolinium enhancing lesions in an MS trial with enhancing lesions on monthly MRIs as the primary outcome (Scicotte et al., 2002), but this too may not occur in a trial using ER beta ligand treatment since enhancing lesions are linked to peripheral immune activation. Estriol treatment reduced relapse rates in an MS trial with relapses as the primary outcome (Voskuhl, 2016). This also may not occur in a trial using ER beta ligand treatment given that enhancing lesions are a biomarker for relapses. However, exploratory outcomes in the estriol Phase 2b trial, designed to detect a decrease in relapse rates, showed that higher estriol levels correlated with improved cognitive function as compared to placebo treatment (Voskuhl, 2016). This was unlikely due to anti-inflammatory effects of estriol since FDA approved disease modifying treatments in MS have not shown significant cognitive improvement over and above placebo treatment during trials. Instead this suggests a direct neuroprotective effect of estriol treatment on cognition (Voskuhl, 2016), as was previously observed in EAE (Ziehn et al., 2012). Given the neuroprotective effects of ER beta ligand treatment in cerebral cortex in EAE (Fig. 3), it is likely that ER beta ligand treatment would also improve cognitive function in an MS trial. Another interesting exploratory finding in the estriol Phase 2b trial was that there was less cerebral cortical gray matter sparing cerebral cortical atrophy by MRI (Fig. 2) and reduced neuronal and synaptic loss (Fig. 3). A major difference between estriol and ER beta ligand treatment in EAE is that estriol was anti-inflammatory during peripheral autoantigen specific responses (Bebo et al., 2001; Kim et al., 1999; Papenfuss et al., 2011), while ER beta ligand treatment was not (Du et al., 2011; Tiwari-Woodruff et al., 2007). Since a role for ER alpha in estrogen mediated anti-inflammatory effects in the immune system have been shown using take away (ER alpha knock out mice) (Liu et al., 2003; Polanczyk et al., 2003) and add back (treatments with ER alpha specific ligands) experiments (Morales et al., 2006), this is likely due to low level ER alpha ligation in the immune system with estriol, but not with ER beta ligand, treatment.
matter atrophy on the MRI timepoint when estriol levels were highest. This sparing of atrophy in cerebral cortex gray matter correlated with improved cognitive performance. Also, it was found in subjects that were enhancing lesion negative, not enhancing lesion positive. Together, these findings suggest direct neuroprotective effects of estradiol treatment in the MS trial (Voskuhl et al., 2016). Based on the above, we hypothesize that sparing of cerebral cortical gray matter atrophy may also occur with ER beta ligand treatment in an MS clinical trial. This hypothesis is supported by the observation here that ER beta ligand treatment spared cerebral cortical atrophy in EAE using *in vivo* longitudinal MRIs (Fig. 2).

Direct neuroprotective effects of treatment with the generic ER beta ligand have been shown using CNS cell specific conditional knock outs of ER beta receptor on oligodendrocytes during EAE, with beneficial effects on remyelination (Crawford et al., 2010; Khalaj et al., 2013). This is however not mutually exclusive of other neuroprotective effects. Striking effects of ER beta ligand treatment were observed herein on both Purkinje cell number and PSD-95, a post synaptic marker on Purkinje cells receiving input from incoming fibers from deep cerebellar nuclei (Fig. 4). This is consistent with expression of ER beta receptor on Purkinje cells (Andrescu et al., 2007; Shughrue et al., 1997), and together suggests direct effects of ER beta ligand treatment on Purkinje cells in the cerebellum. Regarding other potential mechanisms, previous treatment with generic ER beta ligand did not modulate peripheral immune responses or reduce quantitative levels of inflammation in the CNS during EAE (Tiwari-Woodruff et al., 2007). However, qualitative effects on microglia and dendritic cells have been shown (Drew and Chavis, 2000; Du et al., 2011; Papenfuss et al., 2011; Sajo et al., 2011). Whether direct neuroprotective effects of ER beta ligand treatment on microglia/dendritic cells occur in EAE is unknown. Use of conditional knock outs targeting removal of ER beta receptor in cells of the mono-cyte/dendritic cell lineage are needed to distinguish between direct effects of ER beta ligand binding to these cells versus downstream indirect effects.

Mechanisms underlying clinical disease protection in EAE differ depending on the ER beta ligand used. In the current study using the ER beta ligand AC186 (McFarland et al., 2013), a reduction in quantitative levels of macrophages/activated microglia, but not T lymphocytes, in the CNS was observed (Fig. 1). This observation was distinct from results using the generic ER beta ligand DPN, which did not induce quantitative decreases in CD45 or Iba-1 staining in the CNS (Tiwari-Woodruff et al., 2007), even though both treatments spared axons and myelin in spinal cord white matter. The effect of the AC186 treatment on reducing macrophages/activated microglia in spinal cord, with no effect T lymphocytes, would suggest an effect of this particular ER beta ligand on the innate immune system, but not the adaptive immune system. An effect on the innate immune system could represent an additional beneficial mechanism with relevance to chronic progressive disease. Treatment of EAE with another ER beta ligand, LY3201, reduced iNOS and Nfkb expression in microglia and infiltrating T cells (Wu et al., 2013). Also, treatment of EAE with yet another ER beta ligand (Indazole-CI) was anti-inflammatory in peripheral immune responses with subsequent decreases in infiltration of both T cell and macrophages into the CNS (Moore et al., 2014). Thus, while protective effects of treatment with several ER beta ligands have been shown in chronic EAE, the degree to which this is mediated through direct effects on CNS cells versus indirect effects on peripheral immune cells varies based on which ER beta ligand is used. What mediates unique properties of each ER beta ligand remains unknown. The multifaceted nature of mechanisms underlying beneficial effects of ER beta ligand treatments are not surprising given its relationship to estrogen, a hormone with a vast array of biological effects. It is likely that a treatment with multifaceted effects is what is required to impact neurodegeneration in a complex neurodegenerative disease such as MS. The current challenge is to identify the most physiologically relevant biological properties for the design of an ER beta ligand treatment optimized for neuroprotective efficacy with minimal off target effects.

6. Conclusions

Treatment with ER beta ligand as a novel neuroprotective agent for MS is expected to be well tolerated since most deleterious effects of estrogen treatment on breast and uterus are mediated by ER alpha, not ER beta. Standard pharmacokinetic, toxicology, and dose finding studies are needed comparing various ER beta ligands in pre-clinical models as a prelude to the design of a pilot clinical trial in women and men with MS. Given ER beta ligand’s neuroprotective properties, such trials would not be limited to RRMS, but would also include progressive MS. ER beta ligand treatment may slow cerebellar atrophy and brain gray matter atrophy, particularly in the cerebral cortex, suggesting use of these outcomes as biomarkers to detect neuroprotective effects in MS clinical trials testing ER beta ligands.

Funding sources

This work was supported by the National Multiple Sclerosis Society’s Fast Forward Program, the Conrad N. Hilton Foundation (#20150232), the California Community Foundation (#BAPP-15-118094), the Jack H. Skirball Foundation and the Tom Sherak MS Hope Foundation, as well as by the UCLA Laboratories of Neuroendocrinology Training Grant (5T32HD007228).

Conflict of interest disclosure

Dr. Voskuhl in an inventor on patents owned by UCLA for estril treatment in MS. No other authors have conflicts to disclose.

Acknowledgements

We thank Diana Bok, Paula G. Mendoza, Alex Hoffman, and Rojan Kovash for technical laboratory assistance.

References


